Cisplatin引起的听力损失（CIHL）：市场展望、流行病学、竞争格局、市场预测报告，2025-2035年

市场概览

• 德国市场预计将从约 70 万美元成长到约 110 万美元（年复合成长率约 4-5%）。
• 市场规模仍然很小，而且是一个小众领域，但由于人们越来越关注预防性治疗和倖存者护理（例如 STS），因此预计该领域将会成长。

Cisplatin诱发性听力损失（CIHL）概述

Cisplatin诱导性听力损失（CIHL）是一种高发生率、进行性且通常不可逆的双侧感音神经性听力损失，是含铂类药物类化疗的主要剂量限制性毒性。当Cisplatin在耳蜗内积聚并滞留时，会产生过量的活性氧（ROS），从而导致氧化压力，进而引起关键听觉结构（包括外毛细胞、螺旋神经节神经元和血管纹）的细胞凋亡。

临床上，慢性特发性听力损失（CIHL）初期表现为耳鸣和高频率（4000-8000赫兹）听力下降，逐渐扩展至言语频率范围，导致严重的沟通困难。其对儿童的影响尤其严重，可能导致语言发展和神经认知发展迟缓。对成人而言，CIHL 会显着降低生活品质。

治疗需要严格的听力监测，包括在基准和整个化疗过程中进行长时间的高频听力测试和耳声传射（OAE）检查。传统上，由于担心会影响抗癌药物的疗效，预防策略受到限制。然而，近期的进展使得静脉注射硫代硫酸钠（STS）成为首个核准用于儿童病患的保护性药物。在Cisplatin，可在维持肿瘤疗效的同时降低耳毒性，这代表着癌症倖存者护理领域的重大进步。

主要亮点

• 化疗引起的CIHL是一种常见的、不可逆的化疗毒性，具有显着的长期影响。
• 预计美国病例数将从约 378,000 例增加到约 398,000 例（年复合成长率约 0.5%）。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Acousia Therapeutics
• Sensorion

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要治疗方法概述及KOL洞察
• 新兴治疗方法
  • 重点
  • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
  • 值得关注的早期管道

第六章：未满足的需求与TPP分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Cisplatin-Induced Hearing Loss (CIHL) Market Outlook

Thelansis's "Cisplatin-Induced Hearing Loss (CIHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cisplatin-Induced Hearing Loss treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cisplatin-Induced Hearing Loss (CIHL) Overview

Cisplatin-induced hearing loss (CIHL) is a highly prevalent, progressive, and typically irreversible bilateral sensorineural hearing impairment, representing a major dose-limiting toxicity of platinum-based chemotherapy. The condition arises due to the accumulation and prolonged retention of cisplatin within the cochlea, where it generates excessive reactive oxygen species (ROS), leading to oxidative stress and apoptosis of critical auditory structures, including outer hair cells, spiral ganglion neurons, and the stria vascularis.

Clinically, CIHL initially presents with tinnitus and high-frequency hearing loss (4,000-8,000 Hz), which progressively extends into speech frequencies, resulting in significant communication impairment. The impact is particularly severe in pediatric populations, where it can lead to speech, developmental, and neurocognitive delays, while in adults it contributes to substantial quality-of-life deterioration.

Management requires rigorous audiological monitoring, including extended high-frequency audiometry and otoacoustic emissions (OAEs), conducted at baseline and throughout chemotherapy. Historically, preventive strategies were limited due to concerns of compromising anticancer efficacy. However, recent advances have introduced intravenous sodium thiosulfate (STS) as the first approved protective agent in pediatric patients, administered post-cisplatin infusion to mitigate ototoxicity while preserving tumor response, marking a significant advancement in survivorship care.

Key Highlights

• CIHL is a common, irreversible chemotherapy toxicity with significant long-term impact
• US incidence expected to increase from ~378K to ~398K (~0.5% CAGR)

Market Overview

• Germany market projected to grow from ~$0.7M to ~$1.1M (~4-5% CAGR)
• Market remains small and niche, with growth driven by protective therapies like STS and survivorship care focus

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Acousia Therapeutics
• Sensorion

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)